Brian Sullivan, CEO of VIKTORIA-1, refrains from specific comments on achieving top-line data but anticipates its availability soon. Plans include initiating an oncology review post 2Q data, filing NDA within 1-1.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay